Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathilde Jalving

Showing results (1-10 of 78) with videos related to

Pageof 8
Sort By:
Current Opinion in Molecular Therapeutics|August 4, 2009
Induced pluripotent stem cells: will they be safe?Mathilde Jalving, Hein Schepers
The Journal of Clinical Investigation|September 2, 2020
HIFs, angiogenesis, and metabolism: elusive enemies in breast cancerEllen C de Heer, Mathilde Jalving, Adrian L Harris
Nederlands Tijdschrift Voor Geneeskunde|March 27, 2025
[Help with nibs and mabs: targeted cancer therapies for non-oncologists]Matthijs Plas, K Esther Broekman, Thijs H Oude Munnink, et al.
Expert Opinion on Drug Discovery|April 21, 2017
Therapeutic targeting and patient selection for cancers with homologous recombination defectsFrancien Talens, Mathilde Jalving, Jourik A Gietema, et al.
BMC Cancer|March 31, 2017
Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cellsGerke Ariaans, Mathilde Jalving, Emma Geertruida Elisabeth de Vries, et al.
International Journal of Molecular Sciences|April 12, 2022
Pyruvate Dehydrogenase Kinase Inhibition by Dichloroacetate in Melanoma Cells Unveils Metabolic VulnerabilitiesJiske F Tiersma, Bernard Evers, Barbara M Bakker, et al.
Endocrine-Related Cancer|June 27, 2020
The immune tumour microenvironment of neuroendocrine tumours and its implications for immune checkpoint inhibitorsTim J Takkenkamp, Mathilde Jalving, Frederik J H Hoogwater, et al.
Clinical and Translational Allergy|February 5, 2020
Modified protocol of omalizumab treatment to prevent carboplatin-induced drug hypersensitivity reactions: a case studyHanneke N G Oude Elberink, Mathilde Jalving, Hilda Dijkstra, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 17, 2025
Change in Metabolic Markers and the Risk of Skin Cancer: Results from the Lifelines Cohort Study in the NetherlandsMichael Shimelash, Grigory Sidorenkov, Bert van der Vegt, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 25, 2020
Clinically feasible semi-automatic workflows for measuring metabolically active tumour volume in metastatic melanomaJoyce van Sluis, Ellen C de Heer, Mayke Boellaard, et al.
Pageof 8

Showing results (1-10 of 78) with videos related to

Sort By:
Pageof 8
Current Opinion in Molecular Therapeutics|August 4, 2009
Induced pluripotent stem cells: will they be safe?Mathilde Jalving, Hein Schepers
The Journal of Clinical Investigation|September 2, 2020
HIFs, angiogenesis, and metabolism: elusive enemies in breast cancerEllen C de Heer, Mathilde Jalving, Adrian L Harris
Nederlands Tijdschrift Voor Geneeskunde|March 27, 2025
[Help with nibs and mabs: targeted cancer therapies for non-oncologists]Matthijs Plas, K Esther Broekman, Thijs H Oude Munnink, et al.
Expert Opinion on Drug Discovery|April 21, 2017
Therapeutic targeting and patient selection for cancers with homologous recombination defectsFrancien Talens, Mathilde Jalving, Jourik A Gietema, et al.
BMC Cancer|March 31, 2017
Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cellsGerke Ariaans, Mathilde Jalving, Emma Geertruida Elisabeth de Vries, et al.
International Journal of Molecular Sciences|April 12, 2022
Pyruvate Dehydrogenase Kinase Inhibition by Dichloroacetate in Melanoma Cells Unveils Metabolic VulnerabilitiesJiske F Tiersma, Bernard Evers, Barbara M Bakker, et al.
Endocrine-Related Cancer|June 27, 2020
The immune tumour microenvironment of neuroendocrine tumours and its implications for immune checkpoint inhibitorsTim J Takkenkamp, Mathilde Jalving, Frederik J H Hoogwater, et al.
Clinical and Translational Allergy|February 5, 2020
Modified protocol of omalizumab treatment to prevent carboplatin-induced drug hypersensitivity reactions: a case studyHanneke N G Oude Elberink, Mathilde Jalving, Hilda Dijkstra, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 17, 2025
Change in Metabolic Markers and the Risk of Skin Cancer: Results from the Lifelines Cohort Study in the NetherlandsMichael Shimelash, Grigory Sidorenkov, Bert van der Vegt, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 25, 2020
Clinically feasible semi-automatic workflows for measuring metabolically active tumour volume in metastatic melanomaJoyce van Sluis, Ellen C de Heer, Mayke Boellaard, et al.
Pageof 8